Update on the NAEPPCC Asthma Guidelines: The wait is over, or is it? - 03/12/20

Abstract |
As an asthma specialist, one is often asked to discuss the asthma guidelines. The challenge that one faces is deciding which guidelines to use as a resource for discussion or presentation. It often comes down to the following questions: What is the question? What message does one want to deliver? Where is the most current information? and Who is the target audience? This commentary will help answer those questions as it guides the reader through the new update of the National Heart, Lung and Blood Institute/National Asthma Education and Prevention Program guidelines and then outlines differences between 2 widely used strategies for the management of asthma: the Global Initiative for Asthma and the National Heart, Lung and Blood Institute/National Asthma Education and Prevention Program Guidelines for the Diagnosis and Management of Asthma.
Le texte complet de cet article est disponible en PDF.Key words : asthma guidelines, bronchial thermoplasty, inhaled corticosteroids, long-acting ß-agonists, long-acting muscarinic agents, short-acting ß-agonists, tiotropium
Abbreviations used : AHRQ, EPR, EPR-3, EPWG, GINA, ICS, LABA, LAMA, NAEPP, NAEPPCC, NHLBI, SABA
Plan
| Disclosure of potential conflict of interest: S. J. Szefler has consulted for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Genentech, Propeller Health, Regeneron, and Sanofi and has received research support from the National Institutes of Health National Heart, Lung and Blood Institute, Propeller Health, and the Colorado Department of Public Health and Environment’s Colorado Cancer, Cardiovascular and Pulmonary Disease Program. |
Vol 146 - N° 6
P. 1275-1280 - décembre 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
